Background: Obesity and its associated diseases are major health problems characterized 35 by extensive metabolic disturbances. Understanding the causal connections between these 36 phenotypes and variation in metabolite levels can uncover relevant biology and inform novel 37 intervention strategies. Recent studies have combined metabolite profiling with genetic 38 instrumental variable (IV) analyses to infer the direction of causality between metabolites and 39 obesity, but often omitted a large portion of untargeted profiling data consisting of unknown, 40 unidentified metabolite signals. 41
a path to jointly analyze many untargeted datasets with obesity or other phenotypes. This 57 approach, applied to larger datasets with genotype and untargeted metabolite data, should 58 generate sufficient power for robust discovery and replication of causal biological connections 59 between metabolites and various human diseases. 60
INTRODUCTION 61
Abnormal blood metabolite levels are important, frequent, and quantifiable feature of 62 obesity and its associated phenotypes, which are major health problems globally 1-5 . Recently, 63 systematic metabolite profiling (metabolomics) studies have described widespread alterations in 64 the obesity metabolome and identified metabolite markers associated with risk of obesity-related 65 diseases 6-9 . However, these studies broadly have two key analytic challenges limiting the 66 biological interpretation and scope of their findings: these correlative studies have not generally 67 been able to distinguish the cause and effect relationships between metabolites and phenotypes, 68 and only a portion of the thousands of metabolite signals measured by untargeted profiling 69 technology could be chemically identified and thereby routinely investigated. 70
Genetic instrumental variable (IV) analysis (for causal inference) and novel 71 bioinformatics tools (for analysis of untargeted metabolite data) now provide the means to 72 overcome these limitations and enhance our understanding of the metabolome of any phenotype. 73
The genetic IV framework, also known as Mendelian randomization, uses genetic variants as 74 instruments to infer causality from observational data in the presence of unmeasured 75 confounding, provided certain methodological assumptions are met 10, 11 . Bidirectional genetic IV 76 6 identified and curated from profiling data, thus likely capturing only a limited slice of obesity 84 biology and, even within that constraint, not assessing causality. 85
Previously, metabolites of unknown chemical identities -a large portion of untargeted 86 profiling data -were mostly excluded from analyses (including GWAS) because inter-study 87 comparison and biological interpretation were technically onerous or intractable 17, 18 . To address 88 these issues, we recently developed a bioinformatics suite, PAIRUP-MS 18 , to match up unknown 89 metabolites across mass spectrometry-based untargeted profiling datasets, thereby enabling 90 meta-analysis of multiple datasets and increasing statistical power for detecting biologically 91 interesting unknowns. In addition, PAIRUP-MS provides a framework for annotating unknown 92 metabolites using preexisting metabolic pathways and performing pathway analysis 93 incorporating both known and unknown metabolites. 94
In this study, we demonstrate how the combination of bidirectional genetic IV framework 95 and PAIRUP-MS can be used to analyze multiple untargeted metabolomics datasets and 96 characterize causal connections between a phenotype and the metabolome. We identified both 97 known and unknown BMI-associated metabolites, and then performed GWAS for each 98 metabolite and for BMI, followed by bidirectional genetic IV analysis to identify metabolites 99 likely to be causes or effects of obesity. In addition, we highlighted distinct biological pathways both datasets and 1,573 matched unknown or unshared known metabolites) that could be 133 compared directly across OE and MCDS and restricted subsequent analyses to these metabolites. 134
For pathway analyses requiring the BioAge-based metabolite set annotations (see below), we 135 furthered mapped 1,743 (200 shared known and 1,543 matched) of these metabolite pairs to 136 metabolites measured in BioAge. 137
Identifying BMI-associated metabolites: Within each cohort, we adjusted raw BMI 138 (available for 298 OE and 818 MCDS samples) for age and sex, performed rank-based inverse 139 normal transformation on the residuals, and used the resulting BMI z-scores in all further 140 analyses. (Since the OE obese and lean samples were drawn from the BMI extremes of EB, all 141 EB samples were used to calculate population-based z-scores.) To identify BMI-associated 142 metabolites, we performed linear regression of BMI on each metabolite within each dataset, 143 followed by inverse variance weighted meta-analysis across the two datasets, and applied a 144 Bonferroni significance threshold (p < 0.05/1,780) in the meta-analysis. 145
146

Bidirectional instrumental variable analyses (Figure 1b) 147
Metabolite instrument (G M ) selection: GWAS of the BMI-associated metabolites using 148 294 OE and 637 MCDS samples (with available genetic data) and subsequent inverse variance 149 weighted meta-analysis were performed as described previously 18 . To select G M , we first 150 identified the SNP (single nucleotide polymorphism) with the best meta-analyzed p-value for 9 each metabolite. Next, to avoid using redundant G M , we "clumped" the best SNPs for all 152 metabolites to select independent SNPs that have r 2 < 0.5 or are > 250 kb apart, and only kept the 153 independent SNPs as G M (along with their best-associated metabolites) in further analyses. For 154 known metabolites in our causality groups (see below), we performed an additional sensitivity 155 analysis using (where available) genome-wide significant (p < 5 × 10 -8 ) SNPs from published 156 metabolite GWAS 21-26 as individual G M . 157
BMI instrument (G B ) selection:
We used 97 BMI-associated SNPs (G b ) previously 158 identified in GIANT 27 and their effect estimates (β b ) in our UK Biobank (UKB) GWAS to 159 calculate a weighted genetic risk score for use as G B (i.e. G B = Σ β b × G b ). We performed BMI 160 GWAS in UKB using 453,397 European-ancestry samples and sex-combined BMI z-scores, 161 using BOLT-LMM 28 to account for relatedness and population structure (Supplementary Text 162 1). Analysis of the UKB data was approved by its governing Research Ethics Committee and the 163 Broad Institute Institutional Review Board. The GIANT, UKB, and metabolomics cohorts have 164 no known sample overlap. We confirmed that G B was significantly associated with BMI in OE 165 and MCDS and that none of the G b are in linkage disequilibrium (r 2 > 0.3) with the selected G M . 166
Testing for metabolite-to-BMI causal effect using G M : The association between BMI and 167 each G M was extracted from the UKB GWAS summary statistics and used to calculate the Wald 168 ratio IV effect estimate of the metabolite (shared known or matched pair) on BMI. The p-value 169 for the Wald estimate was calculated using an asymptotic standard error estimate as described 170 previously 29 . This p-value -a test of the null hypothesis of no causal effect of the metabolite -171 was used to rank metabolites as more or less likely to be causal for BMI.
1 0 variance weighted meta-analysis. The Wald ratio IV effect estimate of BMI on each metabolite 175 was calculated using the meta-analyzed statistics, and the corresponding p-value was used to 176 rank metabolites as more or less likely to be effects of BMI. As a sensitivity analysis, we 177 performed the MR-PRESSO global test 30 To rank BMI-associated metabolites as more or less likely to be the causes or effects of 184 obesity, we used the -log 10 p-value of the IV effect estimate for either the metabolite (G M ) or 185 BMI (G B ) instrument, reasoning that the statistical significance of these estimates is informative. 186
Metabolites in the top and bottom quartiles of these two p-value-based rankings were assigned to 187 three distinct groups corresponding to different types of causal connections with BMI: (1) 188 "cause": metabolites that were ranked in the top quartile using G M and the bottom using G B , and 189 thus are likely to be upstream causes for BMI ; (2) "effect": metabolites that were ranked in the 190 bottom quartile using G M and the top using G B , and thus are likely to be downstream effects of 191 BMI; (3) "bidirectional": metabolites that were in the top quartiles of both rankings, suggesting 192 complex bidirectional cause-effect relationships with BMI. 193 1 1
ConsensusPathDB 31 were consolidated into 690 metabolite sets with unique metabolite 198 combinations (i.e. one metabolite set may correspond to multiple pathways containing identical 199 sets of metabolites). We then used metabolite correlations in BioAge to expand the metabolite 200 sets to include both known and unknown metabolites, calculating a membership score for each 201 metabolite in each set. 202
Pathway analyses: We applied the pathway analysis framework in PAIRUP-MS to 203 identify enriched metabolite sets for the cause, effect, and bidirectional metabolite groups we 204 defined. We compared each of the three groups individually versus all other BMI-associated 205 metabolites and, in a fourth analysis, compared the cause versus effect groups. First, for each 206 metabolite set in each comparison analysis, a two-tailed Wilcoxon rank-sum test was performed 207 to compare the membership scores of the two groups of metabolites. Next, to account for 208 correlation structure in our data, iterations of this procedure were performed using "null" 209 metabolite groups to calculate a permutation-based enrichment p-value for each metabolite set 210 ( Supplementary Figure 1) . 211 212
Performing m/z query for unknown metabolites 213
To assess if the unknown metabolites captured information redundant to the known 214 metabolites in our dataset (and to look up potential identities of unknowns classified in the three 215 causality groups), we performed m/z query as described previosly 18 , using the "LC-MS Search" 216 tool in the Human Metabolome Database (HMDB) 32 . The unknowns were annotated as an m/z-217 matched adduct of a known metabolite in our data, an m/z-matched adduct of an HMDB 218 metabolite not identified in our data, or as a metabolite without a match in HMDB.
1 2
RESULTS 220
Identifying known and unknown metabolites associated with BMI 221
We used untargeted metabolomics data from OE and MCDS to identify metabolites 222 associated with BMI. First, we identified 207 pairs of shared known metabolites measured in 223 both cohorts, and used PAIRUP-MS to match 1,573 additional pairs of unknown or unshared 224 known metabolites likely to represent identical or highly correlated metabolites. Then, by 225 performing meta-analysis of both the shared known and matched pairs across the cohorts, we 226 identified 577 BMI-associated metabolites at Bonferroni significance (p < 0.05/1,780), the 227 majority of which were unknown metabolites: 418 (72.4%) consisted of two paired unknown 228 metabolites, 59 (10.2%) consisted of a known metabolite matched to an unknown metabolite, 229 and only 100 (17.3%) consisted of shared known metabolites. When we clustered these 230 metabolites, we observed metabolite clusters that consisted mostly or entirely of matched pairs of 231 unknown chemical identities (Supplementary Figure 2) . Therefore, including these unknown 232 metabolites in downstream analyses increased the number of candidate metabolites by nearly 233 five-fold, and allowed us to investigate aspects of obesity biology not represented by the curated, 234 known metabolites. 235
236
Identifying metabolites more likely to be causal for BMI 237 Before we could determine whether the BMI-associated metabolites are likely to be 238 causal for BMI, we first needed to identify the SNP best-associated with each metabolite to use 239 as genetic instrument (G M in Figure 1 ). We therefore performed GWAS of metabolite levels in 240 both OE and MCDS, followed by meta-analysis. We identified genome-wide significant (p < 5 × 241 1 3 (Figure 2); 66 (14 shared known and 52 matched) of these were also significant after correction 243 for multiple hypothesis testing (p < 5 × 10 -8 /577). Overall, the matched, unknown metabolites 244 showed comparable degree of genetic associations as the shared known metabolites, even in loci 245 not associated with any of the knowns. Analyzing the unknowns thus greatly improved our 246 ability to obtain significant and novel genetic instruments for metabolite signals, despite a 247 relatively small GWAS sample size. 248
We observed that all 577 BMI-associated metabolites had best-associated SNPs with at 249 least suggestive significance (maximum p = 2.5 × 10 -6 ) and therefore considered the best-250 associated SNP for each metabolite as potential instrument. To avoid analyzing metabolites 251 sharing the same instruments, we included only genetically independent G M (r 2 < 0.5 or > 250kb 252 apart) and the 324 (40 shared known and 284 matched) metabolites best-associated with these 253 instruments in subsequent IV analyses ( Supplementary Table 1 ). For each metabolite, we 254 estimated the association between G M and BMI using a large independent cohort, UKB, in a two-255 sample design to calculate the metabolite-to-BMI IV effect estimate. We identified 50 (11 shared 256 known and 39 matched) metabolites with nominally significant (p < 0.05) metabolite-to-BMI IV 257 p-values, which indicates that they are more likely to be upstream causes for BMI 258 ( Supplementary Table 1 ). 259 260
Identifying metabolites more likely to be effects of BMI 261
Next, to determine if the BMI-associated metabolites are likely to be effects of BMI, we 262 combined 97 BMI SNPs previously identified in GIANT into a weighted genetic risk score using 263 UKB effect estimates as weights. As expected, the score is a valid genetic instrument for BMI 264 (G B in Figure 1 ) in OE and MCDS (meta-analyzed BMI-G B association p = 5.9 × 10 -7 ). For each In order to further characterize the causal relationships between BMI and its associated 273 metabolites, we ranked the metabolites based on the significance of their G M and G B IV effect 274 estimate p-values (i.e. metabolite-to-BMI or BMI-to-metabolite IV p-values, respectively), and 275 classified a subset of them into "cause", "effect", or "bidirectional" groups using quartile cutoffs 276 of the rankings (Figure 3) . We defined 25 metabolites as more likely to be cause (5 shared 277 known and 20 matched), 26 as more likely to be effect (3 shared known and 23 matched), and 19 278 as more likely to be bidirectional (2 shared known and 17 matched) with respect to BMI. The 279 shared known metabolites in each group are listed in Table 1 ; the top cause, effect, and 280 bidirectional metabolites are alpha-hydroxybutyrate, valine, and glycine, respectively. Details for 281 all metabolites in each group are shown in Supplementary Table 1 . We also performed m/z 282 query in HMDB to obtain potential identities for the unknowns in the matched metabolite pairs 283
( Supplementary Table 2 ) and found only 6 out of the 60 matched pairs to be potentially 284 redundant with the known metabolites curated in our data. Hence, we identified about 5 times 285 more matched, unknown metabolites in the three causality categories compared to only 286 analyzing the known metabolites. In addition, we performed sensitivity analyses to assess how 287 our genetic IV and classification scheme would be influenced by weak instrument or pleiotropy We identified many more matched, unknown metabolite pairs in the cause, effect, and 293 bidirectional groups compared to the shared known metabolites, but it is difficult to hypothesize 294 on their roles in obesity biology without knowing their chemical identities. Therefore, to extract 295 useful information from the unknowns and to gain clues about the biology broadly captured by 296 the three causality groups, we performed PAIRUP-MS pathway analyses encompassing both 297 known and unknown metabolites, using metabolite set annotations generated from a separate 298 cohort, BioAge. First, we carried out three separate analyses to identify pathways with nominally 299 significant (p < 0.05) enrichment for metabolites in the cause, effect, or bidirectional groups, 300 respectively, when compared against all other BMI-associated metabolites (Supplementary 301 Table 4 ). While the most enriched metabolite sets in each analysis are associated with different 302 pathways, several metabolite sets were enriched in multiple analyses (e.g. "NAD de novo 303 biosynthesis" was enriched for both cause and effect metabolites). 304
Hence, in order to identify pathways that are the most distinct between the defined 305 metabolite groups, we next performed a pathway analysis directly comparing the cause versus 306 effect metabolites, prioritizing 40 metabolite sets at nominal significance (p < 0.05; 1 6 27 effect metabolite sets also contain varied pathways including those related to lysine 312 catabolism, neurobiology (e.g. addiction and catecholamine biosynthesis), and stress response 313 (e.g. FoxO signaling). While the known metabolites in our analysis have been linked to some of 314 the enriched metabolite sets in literature, the unknown metabolites contributed most of the data 315 used to prioritize these sets. 316
Finally, to better visualize the distinguishing features between the cause versus effect 317 metabolites in terms of their roles in biological pathways, we constructed a heat map of the 318 metabolites' membership scores in the enriched metabolite sets using unsupervised clustering 319 (Figure 4) . The metabolites formed two major clusters consisting of metabolites that are mostly 320 in the cause or effect groups, with a handful of metabolites clustering with the contrasting group 321 (i.e. cause metabolite "misclassified" in the effect cluster or vice versa). Even more strikingly, 322 the cause and effect metabolite sets formed two pure clusters consisting of all cause or all effect 323 sets. This clustering pattern provides further evidence that the cause and effect metabolites we 324 defined are involved in distinct biological processes and thus may be associated with BMI 325 through different mechanisms. 326
DISCUSSION 327
The study of comprehensive metabolite profiles defines an exciting frontier in human 328 pathophysiology. However, metabolite-phenotype associations discovered in metabolomics 329 studies are often correlative in nature and additional causal inference approaches, such as genetic 330 IV analysis, are required to help assess causality between metabolites and phenotypes. 331 Furthermore, unknown metabolite signals are often filtered out prior to analysis of untargeted 332 metabolomics data, greatly limiting investigation to a priori candidate metabolites, reducing the 333 search space, and hindering downstream analyses such as pathway enrichment. Here we present 334 a paradigm for combining untargeted metabolomics, genomics, and our recently described 335 bioinformatics suite, PAIRUP-MS, to overcome these challenges. Using obesity as an exemplar 336 state of metabolic dysregulation, we illustrate the potential utility of this approach to advance our 337 understanding of causal connections in metabolic diseases. 338
In this study, we meta-analyzed hundreds of unknown metabolites from two cohorts 339 using PAIRUP-MS, identifying novel associations between the unknowns, BMI, genetic 340 variants, and biological pathways. Indeed, using bidirectional genetic IV analysis, we discovered 341 about 5 times as many unknown than known metabolites with potential causal connections to 342 BMI. While these unknowns are likely not all fully independent and functional circulating 343 molecules, their associations with genetic variants and BMI, distinct from those with known 344 metabolites, suggest that a sizable number of unknown metabolites reflect aspects of BMI 345 biology not captured by known metabolites. Furthermore, the much larger number of candidate 346 metabolites allowed us to perform PAIRUP-MS pathway analyses that account for potential 347 redundancy, prioritizing biological pathways specific to the metabolites with cause or effect 348 relationships to BMI. Because of the relatively small sample sizes of our cohorts, some of our 1 8 results did not meet stringent multiple hypothesis testing significance thresholds; nevertheless, 350 they demonstrate a useful and generalizable analytic framework to probe the metabolome of 351 obesity and other diseases as larger datasets become available. 352
We identified novel metabolites that may be causes of obesity, as well as replicating two 353 known metabolites, valine and tyrosine, that may be the effects of BMI 14 . The strongest causal 354 evidence among known metabolites was for alpha-hydroxybutyrate, which has been linked to 355 insulin resistance, oxidative stress, glutathione biosynthesis, and mitochondrial dysfunction 6,33,34 . 356
The oxidative stress and glutathione connections are especially intriguing since "glutathione-357 mediated detoxification" emerged as a significant causal pathway when we compared the cause 358 and effect metabolite groups in pathway analysis. It is also notable that the IV effect estimate of 359 alpha-hydroxybutyrate on BMI is protective while the observational association suggests this 360 metabolite is obesogenic. We postulate that a mitochondrial dysfunction/altered redox state 361 linked to high alpha-hydroxybutyrate level could lead to decreased weight gain, while shared 362 common causes, such as an obesogenic diet, may lead to increases in both alpha-hydroxybutyrate 363 level and BMI. This example highlights the advantage of genetic IV analyses over observational 364 studies alone to explore the potential impact of a theoretical intervention targeted to obesity-365 associated metabolites that have yet to be fully characterized 35, 36 . 366
The validity of genetic IV analysis rests upon several key assumptions. Specifically, the 367 genetic instrument must explain variation in the exposure variable and the instrument must not 368 be associated with the outcome variable except through its relationship with the exposure (no 369 genetic pleiotropy). Weak instrument bias towards the null and pleiotropy bias away from the 370 null may lead to misclassification of metabolites in our three causality groups. To address weak 371 instrument bias for our known metabolite instruments, we performed sensitivity analysis using 1 9 stronger instruments from published metabolite GWAS, showing that our results are generally 373 robust against weak instrument bias, although some misclassification is possible due to limited 374 power of our internal instruments. However, we could not conduct similar analysis for the 375 unknown metabolite instruments since there is not yet a straightforward way to obtain external 376 instruments for comparison. To address pleiotropy bias for our BMI instrument, we used a 377 recently developed method, MR-PRESSO, to show that our BMI IV estimates are likely robust 378 against extreme cases of pleiotropy bias. We could not examine pleiotropy in the metabolite 379 instruments due to the lack of multiple instruments for each metabolite (especially for the 380 unknowns where additional instruments could not be obtained from published GWAS). 381
Larger GWAS of both known and unknown metabolites, conducted across multiple 382 datasets, will make it possible to extend our paradigm to understand causal biological 383 mechanisms for various metabolic diseases and alleviate the limitations described above. With 384 more candidate metabolites and genetic instruments emerging from better-powered studies, our 385 approach can be expanded to mediation analyses 37 , to pathway Mendelian randomization 38 , or to 386 metabolite IV subsetting according to predicted biological pathway memberships 39 . In 387 conclusion, this study showcases the benefit of combining untargeted metabolomics with a 388 bidirectional genetic IV approach to define the metabolome of a major human disease state, 389 obesity. We therefore advocate for broader sharing of untargeted metabolomics and genetic 390 datasets, similar to the approach taken by international efforts to optimize GWAS of many other 391 phenotypes. Broader sharing would improve power and reliability of methodological frameworks 392 such as the one presented here, and would enable a fuller realization of the potential of 393 metabolomics to generate important insights into human diseases. 
